Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bromfenac A · 1 trial · 1 indication
The Ocular Surface Disease Index (OSDI) is a 12 item questionnaire. Each question about discomfort/limitations is scored from 0 to 4, with 0 being 'None of the Time' and 4 being 'All of the Time'. The minimum total score is 0 and the maximum total score is 48, with higher scores indicating worse outcomes.
| Arm | Type | Description |
|---|---|---|
| Bromfenac Ophthalmic Solution A | EXPERIMENTAL | Bromfenac ophthalmic solution A |
| Bromfenac Ophthalmic Solution B | EXPERIMENTAL | Bromfenac ophthalmic solution B |
| Placebo Comparator | PLACEBO_COMPARATOR | Placebo Comparator |
| Name | Type | Description |
|---|---|---|
| Bromfenac Ophthalmic Solution A | DRUG | sterile ophthalmic solution |
| Bromfenac Ophthalmic Solution B | DRUG | sterile ophthalmic solution |
| Placebo Comparator | DRUG | sterile ophthalmic solution |
Inclusion Criteria: * Be of either gender and any race 18 years or older Exclusion Criteria: * Have a local or systemic disease that could interfere with the assessment of safety or efficacy or that is likely to result in early discontinuation from the study
Top 2 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Akebia Therapeutics, Inc. | AKBA | 1 | PHASE2 | Vadadustat |
| Rigel Pharmaceuticals, Inc. | RIGL | 1 | PHASE2 | Fostamatinib |
Bromfenac A is an investigational small molecule being studied for the treatment of dry eye syndrome, also known as dry eye disease. It is being developed by Bausch + Lomb Corporation and is in Phase 3 clinical development. It has not been approved by the FDA for dry eye syndrome.
Bromfenac A targets PTGS2 and PTGS1, also known as cyclooxygenase-2 and cyclooxygenase-1. It is classified as an inhibitor of these enzymes. This mechanism is being investigated in the context of dry eye syndrome, a condition involving ocular surface inflammation.
Bromfenac A is being developed by Bausch + Lomb Corporation, which trades under the ticker BLCO. The company is responsible for the clinical development of this ophthalmic small molecule for dry eye syndrome.
Bromfenac A is in Phase 3 clinical development for dry eye syndrome. It is an investigational therapy and has not been approved by the FDA. The Phase 3 program includes one completed trial, and no active trials are currently listed.
Bromfenac A has been evaluated in one Phase 3 clinical trial, NCT01212471, titled A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease. This completed trial enrolled 840 participants in the United States and was randomized, double-blind, and placebo-controlled.
Yes, Bromfenac A is also known as Bromfenac Ophthalmic Solution A. Both names refer to the same investigational small molecule being developed by Bausch + Lomb Corporation for dry eye syndrome. The alternative name reflects its ophthalmic solution formulation.